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The skin is commonly a¡ected in thyroid diseases, but
the mechanism for this association is still unclear. As
the skin expresses numerous neuroendocrine elements,
we tested the additional cutaneous expression of media-
tors operating in the hypothalamic^pituitary^thyroid
axis.We found signi¢cant expression of the thyroid-sti-
mulating hormone receptor mRNA in cultured kerati-
nocytes, epidermal melanocytes, and melanoma cells.
The presence of thyroid-stimulating hormone receptor
was con¢rmed by northern analyses and the thyroid-
stimulating hormone receptor was found to be func-
tionally active in cyclic adenosine monophosphate
signal assays. Thyroid-stimulating hormone receptor
expressing cells also expressed the sodium iodide sym-
porter and thyroglobulin genes. We also found expres-
sion of deiodinases 2 and 3 (mainly deiodinase 2) in
whole skin biopsy specimens, and in the majority of
epidermal and dermal cells by reverse transcription^
polymerase chain reaction followed by sequencing of
the ampli¢ed gene segments. There was selective ex-
pression of the gene for thyroid-stimulating hormone
b; detection of the thyroid-releasing hormone gene
was minimal and thyroid-releasing hormone receptor
mRNA was not detected in most of the samples.
Expression of functional thyroid-stimulating hormone
receptor in the skin may have signi¢cant physiologic
and pathologic consequences, particularly in autoim-
mune conditions associated with production of stimu-
lating antibodies against the thyroid-stimulating
hormone receptor.We conclude that the expanding list
of neuroendocrine elements expressed in the skin sup-
ports a strong role for this system in cutaneous biology.
Key words: deiodinases/skin/sodium symporter/thyroid-releas-
ing hormone receptor/thyroid-releasing hormone/thyroid-sti-
mulating hormone receptor/thyroid-stimulating hormone.
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T
he skin, the largest body organ, maintains internal
homeostasis by serving as a barrier between the ex-
ternal environment and the internal milieu. To max-
imize the maintenance of its physical and electrical
integrity, the skin is endowed with high sensing cap-
abilities for stressful stimuli and extremely tight spatial control
over the subsequent biologic responses (Slominski and Worts-
man, 2000). Those properties appear to be mediated by a local
neuroendocrine response system tightly coupled to regional
homeostasis (Slominski and Wortsman, 2000; Slominski et al,
2000, 2001). In this regard, fully functional elements of the hy-
pothalamic^pituitary^adrenal axis are expressed in the skin (Slo-
minski andWortsman, 2000; Slominski et al, 2000, 2001).
The skin is also well recognized as a target for thyroid hor-
mones (reviewed in Thiboutot, 1995; Slominski and Wortsman,
2000). Thus, 3,5,30 -triiodothyronine (T3) is involved in epidermal
di¡erentiation, in enhancing local responsiveness to growth fac-
tors, in the physiology of sebaceous, eccrine and apocrine glands,
and in hair growth, besides its stimulating e¡ects on proteoglycan
and glycosaminoglycan production by dermal ¢broblasts (re-
viewed in Thiboutot, 1995; Slominski and Wortsman, 2000).
These e¡ects are probably mediated through interactions with
the speci¢c thyroid hormone receptors (TR), as TRb and TRa
mRNA are present in the skin (reviewed in Slominski and
Wortsman, 2000). In thyroid dysfunction, the skin exhibits typi-
cal abnormalities in hyperthyroidism and hypothyroidism (re-
viewed in Thiboutot, 1995; Slominski and Wortsman, 2000). In
hyperthyroidism, skin changes include erythema, palmoplantar
hyperhidrosis, acropathy, and in¢ltrative dermopathy; also,
Graves’ disease may be associated with generalized pruritus,
chronic urticaria, alopecia areata, vitiligo, and di¡use skin pig-
mentation. In hypothyroidism, the skin is cool, dry with a pasty
appearance; the epidermis is thin and hyperkeratotic; alopecia
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may develop, and there is di¡use myxedema. Interestingly, the
generalized myxedema of hypothyroidism, but not the pretibial
myxedema of Graves’ disease, is fully reversible with thyroid
hormone therapy (reviewed in Thiboutot, 1995; Slominski and
Wortsman, 2000).
Actual in situ production of thyroid hormones in human skin
has not yet been demonstrated, although epidermal keratinocytes
may be capable of deiodinating thyroxine (T4) and T3 (reviewed
in Slominski andWortsman, 2000). Fibroblasts of human dermal
and orbital origin have been reported to express thyroid-stimulat-
ing hormone receptors (TSH-R) (Wu et al, 1996; Stadlmayr et al,
1997; Rapoport et al, 2000). Furthermore, keratinocytes have been
shown to contain thyroid transcription factor-1, an important
regulator of genes important in thyroid hormone formation, in-
cluding the TSH-R (Suzuki et al, 1998a,b). In amphibian verte-
brates (frogs), the skin produces thyroid-releasing hormone
(TRH) in amounts far greater than any other neuroendocrine or-
gan; and this cutaneous TRH reaches the pituitary to stimulate
production of a-melanoctye-stimulating hormone (Vaudry et al,
1999).
We now report skin expression of molecular elements of the
hypothalamic^pituitary^thyroid axis. We tested for an array of
genes that included TRH,TRH-R,TSH,TSH-R, sodium iodide
symporter (NIS), thyroglobulin, and deiodinases 2 and 3 (D2,
D3) in skin cells, using brain, pituitary, and selected peripheral
organs as appropriate controls.
MATERIALS ANDMETHODS
Tissues Specimens of skin [normal and pathologic containing basal cell
carcinoma (BCC)], adrenal gland, thyroid, and myometrium were
collected during surgery, whereas fragments of placenta, umbilical cord,
and fetal membranes were obtained after normal delivery. Pituitaries were
obtained from the National Hormone and Pituitary Program, NIDDK;
whole brain RNAwas purchased commercially. The use of human tissues
was approved by the University of Tennessee Health Science Center
(UTHSC) Committee on Research Involving Human Subjects.
Cells Normal human skin cells tested included neonatal keratinocytes,
adult epidermal and follicular melanocytes and keratinocytes, and dermal
and follicular papilla ¢broblasts. Cells were cultured following standard
protocols as previously described (Tobin and Bystryn, 1996). Established
human skin-derived cell lines that were also tested included immortalized
keratinocytes (HaCaT), squamous cell carcinoma (C4-1), and human
melanoma lines. The latter were established from the radial growth phase
(WM 35 and SBCE2), vertical growth phase (WM 98 and WM 1341D),
metastasis (WM 164) (gift of Dr M. Herlyn,Wistar Institute, Philadelphia,
PA), and SKMEL188 melanoma that expresses the melanotic phenotype
when cultured in Dulbecco minimal Eagle’s medium (Slominski et al,
Table I. List of primers used for reverse transcription^PCR ampli¢cation
Gene Primers Primer location PCR product size (bp)
TSHb First pair of primers
CTAACCATCAACACCACCATCTG (sense) exon 1
GGTTTGGTACAGTAGTTTGTCTTG (anti-sense) exon 2
Nested primers
CCACCATCTGTGCTGGATATTG (sense) exon 1
(TATTGCACTTGCCACACTTACAG (anti-sense) exon 2 198 bp
TSH-R First pair of primers
AATCCCTGTGAATGCTTTTC (sense) exon 6
ACTCAAGGAAAGTGGAAGTT (anti-sense) exon 10
Nested primers
GTGAATGCTTTTCAGGGACTATG (sense) exon 6
GTCCAGGTGTTTCTTGCTATCAG (anti-sense) exon 10 272 bp
Primers used for direct PCR
GGGTGCAACACGGCTGGTTT (sense) exon 10
CTGGGTTGTACTGCGGATTTCGG (anti-sense) exon 10 367 bp
TRH First pair of primers
TTGCTGCTCGCTCTGGCTTTG (sense) exon 2
CTGGCGTTTTTCAGGCATCAG (anti-sense) exon 3
Nested primers
CTCTTCCTCCGGGAAAACATC (sense) exon 2
CTCTTCTTCCCAGCTCCTTTG (anti-sense) exon 3 354 bp
TRH-R First pair of primers
GCCTCTGCATTACTTACCTCCAG (sense) exon 1
GGTCTGACTCCTTGATGACGCTG (anti-sense) exon 2
Nested primers
ACTGTATGCTCTGGTTCTTCTTG (sense) exon 1
GTTTCTCTGTTGGCTTCTGCTTG (anti-sense) exon 2 567 bp
D2 First pair of primers
TGCCTCTTCCTGGCTCTCTATG (sense) exon 1
CAAAGGCTACCCCGTAAGCTATG (anti-sense) exon 2
Nested primers
ATGACTCGGTCATTCTGCTCAAG (sense) exon 1
CTGGGTACCATTGCCACTGTTG (anti-sense) exon 2 227 bp
D3 GCCTTCATGCTCTGGCTTCTC (sense) exon 1
TAGTCGAGGATGTGCTGGCTC (anti-sense) exon 1 296 bp
NIS CTGCCCCAGACCAGTACATGCC (sense) exons 7^8
TGACGGTGAAGGAGCCCTGAAG (anti-sense) exons 10^11 303 bp
Thyroglobulin CCGCCGTCATCAGCCATGAG (sense) exon 42
TGAGTCCTCGCCACCCAGAGAA (anti-sense) exon 44 395 bp
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1998). Rodent cell lines included the melanomas, hamster AbC1 and mouse
S91. The culture conditions have been described in detail (Slominski et al,
1998, 1998, 1999). Rat FRTL-5 thyroid cells (ATCC CRL 8305; Interthyr
Research Foundation, Baltimore, MD) were a fresh subclone (F1) that had
all the functional properties previously detailed (Kohn et al, 1986; Suzuki
et al, 1998a,b). Cells were diploid and between their ¢fth and 25th passage.
They were grown in 6H medium with additions described previously
(Kohn et al, 1986). To maximize TSH-R gene expression in these
experiments (Saji et al, 1992), cells were maintained in 5H medium that
contains no TSH for 5 d before use. Nonfunctioning FRT thyroid cells
were grown in Coon’s modi¢ed F-12 medium (Sigma, ST. Louis, MO)
containing 5% heat-treated, mycoplasma-free calf serum (Gibco
Laboratories Life Technologies, Inc., Grand Island, NY), glutamine, and
1 mM nonessential amino acids (Suzuki et al, 1998b).
Reverse transcription^polymerase chain reaction (reverse
transcription^PCR) assays Total RNA was extracted using Trizol
isolation kit (Gibco-BRL, Gaithersburg, MD). The synthesis of ¢rst-
strand cDNA was performed using the Superscript preampli¢cation
system (Gibco-BRL). Five micrograms of total RNA per reaction was
reverse transcribed according to the manufacturer’s protocol using
oligo(dT) as the primer. Expression of genes having only one coding
exon was evaluated using cDNA samples that were synthesized from
DNase-treated poly(A) mRNA. Lack of DNA contamination was
con¢rmed by negative ampli¢cation of RNA without prior reverse
transcription.
All samples were standardized by the ampli¢cation of housekeeping
gene GAPDH as described previously (Pisarchik and Slominski, 2001).
The reaction mixture (25 ml) contained 2.5 mM MgCl2, 2.5 mM of each
deoxyribonucleoside triphosphate, 0.4 mM of each primer, 75 mM Tris^
HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween 20, and 0.25 U of Taq
polymerase (Promega, Madison,WI). The mixture was heated to 941C for
2.5 min and then ampli¢ed for 35, 30, or 25 cycles as speci¢ed: 941C for
30 s (denaturation), 601C (TSHb, TRH-R, D2, D3 genes, and ¢rst PCR
round of TSH-R) or 551C (TRH gene and second PCR round of TSH-
R) for 40 s (annealing) and 721C for 1 min (extension).
Human TSHb (accession no. XM___002123), TSH-R (accession no.
NM___000369), TRH (accession no. NM___007117), TRH-R (accession no.
NM___003301), and D2 genes (accession no. AF093774) were ampli¢ed by
nested PCR. Gene D3 (accession no. NM^001362) was ampli¢ed in one
PCR reaction.We never ampli¢ed D3 gene for more than 25 cycles and
used an appropriate amount of RNA as a control for DNA
contamination for each sample. Sequences of the primers used for PCR
ampli¢cations are listed inTable I.
Ampli¢cation products were separated by agarose gel electrophoresis and
visualized with ethidium bromide staining. The identi¢ed PCR products
were excised from the agarose gel and puri¢ed by GFX PCR DNA and
gel band puri¢cation kit (Amersham Pharmacia Biotech, Piscataway, NJ).
PCR fragments were cloned in pGEM-T easy vector system (Promega)
and puri¢ed by plasmid puri¢cation kit (Qiagen, Valencia, CA).
Sequencing was performed in the Molecular Resource Center at the
University of Tennessee HSC (Memphis) using Applied Biosystems 3100
Genetic Analyzer and BigDyet Terminator Kit (Applied Biosystems,
Foster City, CA).
To detect NIS (accession no. NM____000453), thyroglobulin, and TSH-R
(accession no. NM____000369) gene expression in HaCaT keratinocytes and
human melanomas the RNA was puri¢ed free of genomic DNA using
DNA-Free (Ambion, Austin, TX) according to recommended conditions.
cDNA was synthesized from 1.0 mg of total RNA using MMLV reverse
transcriptase with random-hexamer primers (Clontech, Palo Alto, CA).
Polymerase chain reaction (50 ml) was performed using 3% of the total
cDNA in a reaction mixture containing 10 mM Tris^HCl, pH 8.3, 50 mM
KCl, 3.5 mM MgCl2, 0.01% gelatin, 0.25 mM each deoxyribonucleoside
triphosphate, 0.4 mM of each primer, 1.0 U AmpliTaq polymerase (Perkin-
Elmer, Norwalk, CT), and 0.2 mg TaqStart antibody (Clontech). The
primers used are in Table I. Ampli¢cations conditions were: polymerase
activation at 951C for 5 min; 35 (thyroglobulin and TSH-R) or 40 (NIS)
cycles of denaturation at 941C for 20 s, annealing at 641C for 1 min
(thyroglobulin and TSH-R) or 701C for 1 min (NIS), and extension at
721C for 1 min; followed by 721C for 7 min.
Northern blot analyses Total RNA was prepared using a commercial
kit (RNeasy Mini Kit, Qiagen). Fifteen micrograms of RNA samples
were run on denatured agarose gels, blotted on Nytran membranes
(Schleicher & Schuell, Keene, NH) and subjected to hybridization as
described (Saji et al, 1992; Giuliani et al, 1995; Suzuki et al, 1998a,b). Full
length rat or human TSH-R radiolabeled with [a-32P]deoxycytidine
triphosphate were used as probes (Tahara et al, 1991).
Cyclic adenosine monophosphate (cAMP) assays The noted
concentration of bovine TSH, in units described by the manufacturer
(Sigma), or 100 ml (0.5 mg) of a standard anti-TSH-R stimulating
antibodies were added with fresh medium to cell samples cultured in 24
well plates then incubated for 2 h in the presence of 0.5 mM of
isobuthylmethylxanthine at 371C in 5% CO2. The concentrations of
extracellular cAMP were measured with a nonacetylation enzyme
immunoassay using the BIOTRAK cAMP enzyme immunoassay system
as recommended by the manufacturer (Amersham Pharmacia Biotech).
The cAMP concentration of samples was expressed as a level of
stimulation relative to control incubations with no TSH or stimulating
TSH antibodies.
RESULTS AND DISCUSSION
Expression of functional TSH-R in skin cells As previous
reports suggested TSH-R expression in the human skin (Wu et
al, 1996; Stadlmayr et al, 1997; Rapoport et al, 2000), we tested
expression of the gene by reverse transcription^PCR in a broad
panel of specimens. Expression of the TSH-R gene 272 bp
product of nested PCR (not shown) and the 367 bp product of
direct PCR (Fig 1) was found in almost all tissues tested,
including normal and pathologic skin; exceptions being the
umbilical cord and myometrium (Table II). TSH-R was also
detected in cultured dermal and follicular papilla ¢broblasts,
neonatal, follicular and immortalized HaCaT keratinocytes,
squamous cell carcinoma cells, epidermal melanocytes, and in
four melanoma lines. TSH-R gene expression was below
detectable levels only in follicular melanocytes and in two
melanoma lines (Table II). Northern blot analysis was then
performed in selected human and rodent melanoma lines, and in
human squamous cell carcinoma cells and immortalized
epidermal keratinocytes. This revealed a TSH-R transcript of 3.3
kb, similar to aTSH-R transcript detected in control rat FRTL-5
thyroid cells (Fig 2). This transcript encoded a functional TSH-R
as documented by strong responses toTSH and antibodies against
TSH-R, e.g., marked stimulation of cAMP production in human
Figure1. Expression of TSH-R, thyroglobulin, and NIS genes in
cultured cells. On the right the arrows identify reverse transcription^
PCR products of TSH-R (367 bp), NIS (303 bp), and thyroglobulin (395
bp) transcripts. (1) HaCaT keratinocytes; (2^4) WM 35,WM 164, andWM
1341D, SBCE2 respectively; (5) SKMEL188 melanoma; (6) negative control
no template; (7,8) normal thyroid. Left: Gibco-BRL Kb Plus ladder.
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melanoma, in keratinocytes, in hamster melanoma (Table III)
and in mouse melanoma (not shown).
The presence of TSH-R transcripts in dermal ¢broblasts or in
skin biopsies had previously been shown (Rapoport et al, 2000;
Wu et al, 1996; Stadlmayr et al, 1997), and expression of thyroid
transcription factor-1 (positive transcriptional regulator of TSH-
R gene) (Shimura et al, 1994) had also been detected in
keratinocytes (Suzuki et al, 1998a,b). What is novel is the
detection of TSH-R in the main cellular components of
epidermis and hair follicles (with the exception of hair follicle
melanocytes) with strong functional activity. This ¢nding
would have clinical relevance to explain some of the cutaneous
symptoms of Graves’ disease (Thiboutot, 1995). Thus, the
observed expression of TSH-R on epidermal melanocytes may
be connected with the skin pigmentation of Graves’disease as its
intracellular mediator, cAMP acts as stimulator of melanocytes
proliferation and di¡erentiation. Indeed, both human and rodent
malignant melanocytes and keratinocytes showed that TSH
and anti-TSH-R antibodies stimulated cAMP production
(Table III). Alternatively, expression of the TSH-R may turn
melanocytes into targets for the destruction by TSH-R
autoantibodies, thus explaining the high incidence of vitiligo
in patients with Graves’ disease (Slominski et al, 1989). Also
intriguing is the presence of TSH-R on hair follicle
keratinocytes and papilla ¢broblasts that might be involved in
the association of Graves’ disease with alopecia areata. Finally,
taken together with previous ¢ndings (Wu et al, 1996; Stadlmayr
et al, 1997; Rapoport et al, 2000), the present observations raise the
tantalizing prospect that some forms of Graves’ disease could be
due to an autoimmune response directed primarily against a
cutaneous TSH-R antigen. Thus, this could result from
abnormal expression of major histocompatibility complex
proteins, and abnormal exposure of TSH-R antigen to immune
cells (Shimojo et al, 1996; Suzuki et al, 1999; Kohn et al, 2000),
in response to exposure to environmental insults, e.g., solar
radiation or skin infections.
In the thyroid, TSH-R-stimulated pathways regulate most
aspects of intracellular iodide and thyroglobulin metabolism,
synthesis of NIS and production, and secretion of T4 (Kohn et
al, 2000).We therefore evaluated the possibility of similar e¡ects
in the skin. Using reverse transcription^PCR we tested skin
expression of TSH-R-regulated genes in vitro in stable cell lines
positive for TSH-R (HaCaT keratinocytes and four di¡erent
melanoma lines, e.g., SWM 35,WM164,WM1341D), and also in
one line negative for TSH-R (SKMEL188). The lines expressing
TSH-R also coexpressed thyroglobulin and NIS genes, whereas
the SKMEL188 line was negative for these genes (Fig 1). All of
Table II. Pro¢le of D2, D3,TSH-R,TSH,TRH-R, and TRH genes expression in human tissues and cultured skin cells
Genes
Specimens TSHb TRH TRH-R D2 D3 TSH-R
Tissues
Brain (whole) ^ þ þ þ þ þ
Pituitary þ ^ þ þ þ þ
Skin (normal) ^0/4) þ 1/4 ^(0/4) þ 4/4 þ 4/4 þ 3/3
Skin (involved by BCC) ^(0/3) ^(0/3) þ 1/3 þ 3/3 þ 3/3 þ 2/2
Adrenal gland ^ þ ^ þ þ þ
Myometrium þ þ ^ þ þ ^
Placenta ^ þ ^ þ þ þ
Umbilical cord ^ þ ^ þ þ ^
Fetal membrane ^ þ ^ þ þ þ
Cultured cells
Neonatal keratinocytes ^ þ ^ þ þ þ
Epidermal keratinocytes þ ^ ^ þ þ þ
Hair follicle keratinocytes þ ^ ^ þ þ þ
HaCaT keratinocytes ^ ^ ^ þ þ þ
Epidermal melanocytes ^ ^ ^ þ ^ þ
Hair follicle melanocytes þ ^ ^ ^ ^ ^
Melanoma SKMEL188 þ ^ þ þ ^ ^
Melanoma SBCE2 ^ þ ^ þ ^ þ
MelanomaWM35 ^ ^ ^ þ ^ þ
MelanomaWM98 ^ ^ ^ þ ^ ^
MelanomaWM164 þ ^ ^ þ ^ þ
MelanomaWM1341D ^ þ þ þ þ þ
Dermal ¢broblasts ^ þ ^ þ þ þ
Hair follicle papilla ¢broblasts ^ þ ^ þ þ þ
Squamous cell carcinoma C1^4 þ ^ ^ þ ^ þ
In parentheses: (no. of positive/no. of biopsies tested)
Figure 2. Northern blotting detection of TSH-R gene expression in
skin cells. (A) RNA transcripts hybridizable to TSH-R cDNA; (B) ethi-
dium bromide stain of corresponding total RNA. Following cell lines are
presented: positive control represented by FRTL-5 thyroid line (1); human
melanomasWM35 (2) andWM164 (7) lines; human C1-4 squamous cell car-
cinoma (3) and HaCaT keratinocytes (4); hamster AbC1 melanoma (5);
mouse S91 melanoma (6).
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these lines were negative for thyroid peroxidase gene (not
shown). Thus, expression of some, but not all molecular
elements of the TSH-R-related pathways that are characteristic
for the thyroid is conserved in cultured skin cells.
Recent studies have shown NIS expression in lactating breast
tissue and in some breast cancers (Spitzweg et al, 2001). TSH-R
has been found on fat cells and other nonthyroid tissues
(Szkudlinski et al, 2001). Functional roles have not been fully
clari¢ed for NIS in breast tissue or TSH-R in fat tissue, nor is it
clear why such genes might be expressed in a pathologic
situation. The existence of TSH-R in melanoma cells might be
exploited if the TSH-R is involved in the regulation of growth
or function of these cells as might be the case for NIS in breast
cancer. Growth and function studies are in progress in our
laboratories.
Reverse transcription^PCR assays for TSHb, D2, D3, TRH-
R, and TRH We used the reverse transcription^PCR
technique with sequencing of the ampli¢ed gene products
together to de¢ne cutaneous expression of the genes coding for
TSHb, D2, D3, TRH-R, and TRH genes, in a combination of
human tissue and cultured skin cells (Fig. 3;Table IV).
TSHb As we had found functional expression of TSH-R in the
skin, we tested for its natural ligand (TSHb) to investigate para-
crine or autocrine control of TSH-R activity. Aside from its ex-
pression in the pituitary control, TSHb gene expression was
observed in epidermal and hair follicle keratinocytes, hair follicle
melanocytes, squamous cell carcinoma, and two melanoma lines,
as well as myometrium, being absent in all other cells or tissues
tested that included biopsies of whole skin (Fig 3A; Table II).
This pattern suggests that TSH expression is not constitutive,
but instead responds to environmental stimulation exempli¢ed,
in this case, by the conditions of cell culture and/or by random
depression during malignant progression.
D2 and D3 genes The D2 gene product (227 bp) was expressed in
almost all tested samples; the sole exception was a line of hair
follicle melanocytes where it was below detectable levels (Fig 3B;
Table II). In some biopsies of normal skin (one of four) and skin
containing BCC (one of three), an additional second transcript of
335 bp was detected. It corresponds to the b isoform of D2 (D2b,
accession no. AB041843). D2b contains an additional exon (inser-
tion of 108 bp) with an in-frame TGA codon that may encode
an extra selenocysteine (Ohba et al, 2001). This second isoform
(335 bp) was also present in neonatal, epidermal, follicular and
HaCaT keratinocytes, dermal and follicular papilla ¢broblasts,
epidermal melanocytes, squamous cell carcinoma cells,
and the SBCE2 melanoma line (Fig 1B). The detection of
the second isoform is consistent with the recent ¢ndings of
two additional splicing variants of human D2 di¡erentially
expressed in brain, kidney, lung, and trachea (Ohba et al,
2001).
The D3 gene was expressed in all tissues tested that included
brain, pituitary, adrenal gland, and intrauterine tissues. It was also
detected in skin, where its expression was cell type speci¢c
Table III. TSH stimulation of TSH-R in hamster (AbC-1) and human (WM 164) melanoma cells and immortalized
normal human keratinocytes (HaCaT) compared with thyroid cell lines (FRTL-5 and FRT) signal transduction is coupled
to cAMP production
Relative cAMP increase during 2 h incubation
Bu¡er TSH TSH Anti-TSH receptor antibodies
Cell line (control) (1 mU per ml) (10 mU per ml) (1 mg per ml)
AbC-1 1 6.7 25.9 4.2
WM 164 1 3.6 6.1 2.8
HaCaT 1 1.5 5.2 3.2
FRTL-5 1 7.1 7.1 4.1
FRT 1 0.9 0.8 1.1
The values represent means from duplicate assays of a representative experiment. The data are presented as relative cAMP levels compared with control (addition of
media alone).
Figure 3. Expression of thyroid-related genes in human tissues. (A)
Expression of TSHb: (1) DNA ladder; (2) pituitary; (3) follicular melano-
cytes; (4) SKMEL188 melanoma; (5) WM164 melanoma; (6) follicular ker-
atinocytes; (7) epidermal keratinocytes; (8) dermal ¢broblasts; (9) hair
follicle papilla ¢broblasts; (10) HaCaT keratinocytes. (B) Expression of D2
in human skin samples: (1,13) DNA ladder; (2) normal skin; (3) BCC; (4)
HaCaT keratinocytes; (5) neonatal keratinocytes; (6) follicular keratino-
cytes; (7) epidermal keratinocytes; (8) neonatal keratinocytes; (9) dermal
¢broblasts; (10) hair follicle papilla ¢broblasts; (11) SKMEL188 melanoma;
(12) SBCE2 melanoma. Arrows marked 227 bp (D2a) and 335 bp (D2b)
transcripts. (C) Expression of D3 in human tissues and skin cells: (1,9)
DNA ladder; (2) pituitary; (3,4) normal skin; (5) BCC; (6) myometrium;
(7) follicular keratinocytes; (8) epidermal keratinocytes; (10) epidermal mel-
anocytes; (11^13) SBCE2,WM35, andWM98 melanomas, respectively. (D)
Expression of TRH-R: (1) DNA ladder; (2) pituitary; (3,4) SKMEL188 and
WM1341D melanomas, respectively. (E) Expression of TRH: (1,10) DNA
ladder; (2) nonlesional human skin; (3) dermal ¢broblasts; (4) hair follicle
papilla ¢broblasts; (5) melanomaWM1341D; (6) neonatal keratinocytes; (7)
adrenal gland; (8) myometrium; (9) placenta.
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(Fig 3C). It was expressed in all tested keratinocytes and ¢bro-
blasts lines, but was absent in melanocytes and in the majority
of melanoma lines (¢ve of six) (Table II).
D2 catalyzes 50 (outer ring) deiodination of T4 to T3, whereas
D3 catalyzes 5 (inner ring) deiodination of T4 and T3 to inactive
T3 (rT3) and 3,30 -diiodothyronine (T2) (St Germain, 1999; Bianco
et al, 2002). The structure of both genes is brown. D2 is predomi-
nantly expressed in pituitary, brain, brown fat, thyroid, heart, and
skeletal muscle, whereas D3 is predominantly expressed in the
brain, uterus, placenta, fetal membranes, and skin (rodents) (St
Germain, 1999). Actual transformation of T4 to T3, and of T3 to
T2 have been demonstrated in cultured epidermal keratinocytes
(Kaplan et al, 1988), although the pattern of expression of the cor-
responding genes has not been evaluated in human skin. Our
data thus represent the ¢rst demonstration of D2 and D3 gene
expression in human skin. A di¡erential pattern for expression
of the genes becomes clearly evident along the predominant cel-
lular components of the epidermis and dermis. The absence of
D2 in hair follicle melanocytes and of D3 in both epidermal
and hair follicle melanocytes, in the majority of melanoma cells
and in the squamous cell carcinoma line suggest cell lineage spe-
ci¢c gene expression and probably, of correspondingly speci¢c
patterns of T3 degradation in the same populations. Future bio-
chemical studies on the di¡erential pattern of cell type speci¢cT3
production and degradation should clarify the functional impli-
cations at the systemic level, and in epidermal and dermal home-
ostasis and activity of adnexal structures.
TRH and TRH-R As TSH production is under the control of
hypothalamic TRH, we evaluated local expression of the TRH-
R gene. As expected, expression of TRH-R gene was found in
brain and pituitary. In the skin, it was detected only in a single
skin biopsy specimen of BCC, and in two melanoma lines
SKMEL188 and WM1341D (Fig 3D; Table II). Thus, TRH-R
may not participate directly in the physiology of the skin. Con-
versely,TRH that was detected in brain, adrenal gland, myome-
trium, placenta, umbilical cord, and fetal membrane, was also
widely present in skin cells. It was found in normal skin (in one
of four biopsies), in four melanoma lines, in neonatal keratino-
cytes and in both dermal and follicular papilla ¢broblasts (Fig
3E,Table II). Therefore, TRH is not coexpressed with TRH-R
in most cells (with exception of SKMEL188 melanoma) suggest-
ing that paracrine or autocrine mechanisms may not operate lo-
cally in peripheral tissues, e.g., skin, placenta, fetal membranes,
uterus, and adrenal gland. It can be speculated that expression of
TRH mRNA by the above tissues and cell types may result in
TRH production mainly for export, to regulate regional (skin
¢broblasts, adrenal gland) or fetal (placenta, umbilical cord, fetal
membranes) homeostasis. Of note, amphibian skin regulates pi-
tuitary function through local production of TRH that is ex-
ported to stimulate pituitary production and release of prolactin
and a-melanoctye-stimulating hormone (Vaudry et al, 1999).
Thus, this peptide gene expression may very well represent an
evolutionary continuum.
CONCLUSIONS
There is broad cutaneous expression of the gene and functional
TSH-R, which is still of undetermined physiologic and patholo-
gic signi¢cance. Genes for elements of the hypothalamic^pitui-
tary^thyroid axis are also expressed in the skin, but with
selectivity in both cell type and gene type. It appears that there
may be important divergences between the roles of the molecules
at the central and peripheral levels.
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